The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Mucinous Adenocarcinoma

Mucinous Adenocarcinoma

Mucinous Adenocarcinoma is a type of adenocarcinoma characterized by the presence of mucin within the tumor cells.
This malignant neoplasm can occur in various organs, such as the colon, rectum, pancreas, and ovaries.
Mucinous adenocarcinoma is often associated with a poorer prognosis compared to other adenocarcinoma subtypes due to its unique biological features and clinical presentation.
Researchers and clinicians can leverage the power of PubCompre.ai's AI-driven platform to enhance reproducibility and accuracy in the study of this complex disease, facilitating the discovery of the best protocols from literature, preprints, and patents through intelligent comparisons and data-driven insights.
PubCompare.ai's state-of-the-art technology enables seamless research, empowering users to make more informed decisions and advance the understanding of Mucinous Adenocarcinoma.

Most cited protocols related to «Mucinous Adenocarcinoma»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Adenocarcinoma Adenocarcinoma in Situ Lung Neoplasms Mucinous Adenocarcinoma
The 2695 cases and 2777 controls from the E2C2 consortium were genotyped using the Illumina Human OmniExpress array (2271 cases, 2219 controls from the United States) or the Illumina Human 660W array (424 cases, 558 controls from Poland)33 (link) and both sets were separately imputed to the 1000 Genomes Project v3 reference panel using “minimac2” software, following standard quality control steps38 (link),39 (link).
The 288 cases from six population-based case–control studies within the Women’s Health Initiative were genotyped using five different arrays (Supplementary Data 1) and were each separately imputed using the combined 1000 Genome Project v3 and UK10K reference panels using “minimac2” software39 (link), following standard quality measures and the exclusion of SNPs with a MAF <1%. Five controls for each case were selected randomly, matched on study.
Data were also included from the first phase of UK Biobank genotyping, comprising 636 Cancer Registry-confirmed endometrial cancer cases (as of October 2016) and 62,853 cancer-free female controls. Samples were genotyped using Affymetrix UK BiLEVE Axiom array and Affymetrix UK Biobank Axiom® array and imputed to the combined 1000 Genome Project v3 and UK10K reference panels using SHAPEIT340 (link) and IMPUTE341 .
No analyses to identify duplicates or relatives between samples from the E2C2, WHI, or UK Biobank studies, and any other study were carried out. However, given the sampling frame of these studies, it is very unlikely that there would have been any meaningful sample overlap.
After QC exclusions, the analysis included 12,906 endometrial cancer cases (3613 of which have not been included in any previous publication) and 108,979 controls. Analyses were also carried out specifically for endometrial cancer of endometrioid histology (8758 cases) and endometrial cancer with non-endometrioid histology (1230 cases). Exploratory analyses for specific non-endometrioid histologies (serous carcinoma, carcinosarcoma, clear cell carcinoma, and mucinous carcinoma) included a small number of cases of mixed histotype, where the major component was non-endometrioid. The UK Biobank data did not include information about histology.
All participating studies were approved by research ethics committees from QIMR Berghofer Medical Research Institute, University-Clinic Erlangen, Karolinska Institutet, UZ Leuven, The Mayo Clinic, The Hunter New England Health District, The Regional Committees for Medical and Health Research Ethics Norway, and the UK National Research Ethics Service (04/Q0803/148 and 05/MRE05/1). All participants provided written, informed consent.
Full text: Click here
Publication 2018
Adenocarcinoma, Clear Cell Carcinosarcoma Endometrial Carcinoma Endometrium Ethics Committees, Research Genome Homo sapiens Malignant Neoplasms Mucinous Adenocarcinoma Reading Frames Serous Cystadenocarcinoma Single Nucleotide Polymorphism Woman
We identified a set of gene sets that were associated with different endpoints related to tumor histology. Signatures for each of the following scenarios was created: right/left (RT/LT) colon was computed by comparing 60 samples collected in RT Colon vs. 18 samples collected in LT Colon; Mucinous/Non-Mucinous colon carcinoma was developed by comparing 35 mucinous colon carcinomas vs. 165 non-mucinous; MSI/MSS was created by comparing 6 MSI vs. 73 MSS samples; Carcinoma vs. Adenoma was developed by comparing 22 pure adenocarcinoma samples vs. 5 pure adenomas; Poor/Well differentiation was discovered by comparing 32 poorly differentiated samples vs. 19 well differentiated, Colon/Rectum by comparing 50 samples collected in colon vs. 19 samples collected in rectum; Stage2/Stage1 was identified by comparing 59 stage 2 samples vs. 32 stage 1 samples, Stage3/Stage2 (71 Stage3 samples vs. 59 Stage2 samples) was similarly identified. Each comparison was carried on non-metastatic samples with known stage, histology, and collection site. For each comparison, two gene sets (up and down regulated) were identified by t-test with p-value < 0.01, split by a sign of fold change, selection of unique gene symbols among 100 probes most differentially expressed by an absolute value of fold change. Performance of these gene sets was evaluated by back substitution and the scores for gene sets were computed as the mean of probes mapped by the gene symbol to the up-regulated subset minus the mean of the probes that mapped by the gene symbol to the down-regulated subset. They were found to have ROC AUC>0.7 and 1-way ANOVA p-value < 1e-6 when applied to distinguish the same samples that were used to identify these gene sets.
Full text: Click here
Publication 2011
Adenocarcinoma Adenoma Carcinoma Colon Genes Genes, vif Genetic Selection Lanugo Mucinous Adenocarcinoma Mucins Neoplasms neuro-oncological ventral antigen 2, human Rectum
Patients’ entire prostatectomy slide sets were rereviewed. The slides containing cancer (average ± SD per case, 8.0 ± 4.3) were digitally scanned as virtual slides using a ScanScope XT (Aperio Technologies, Vista, CA). By using ImageScope software (Aperio), we manually annotated all foci of 9 histologic patterns in a nonoverlapping manner, using a different color for each pattern, denoted as follows: (1) S, single, separate small acini, like 3B pattern3 (link) without blue mucin Image 1A; (2) B, single, separate small acini with blue mucin Image 1B; (3) U, undulated, stellate, or branching medium acini, like 3A pattern3 (link) lined by a single cell layer Image 1C; (4) F, fused, ragged small acini, including those with mucin Image 1D; (5) P, (micro)papillary consisting of medium to large spaces with stromal cores or strands of cells with 1 or more cell layers bridging across the acinus, with intervening slit-like spaces Image 1E; (6) SC, small cribriform, mediumsized acinar spaces with rounded contour, no solid foci, and 12 or fewer lumen spaces (inclusive of the glomeruloid pattern18 (link)) Image 1F; (7) LC, large cribriform, with expansive cribriform to focally solid large acini with more than 12 lumen spaces Image 1G; (8) I, individual infiltrating or sheet-like cells lacking lumen formation Image 1H; and (9) M, mucinous (colloid) carcinoma in which nonfused acini (excluding single cells) floated in mucin pools Image 1I. Note that although the lumen contours of the U and P patterns were somewhat similar, strict criteria (as stated) were adhered to for P, (micro)papillary. Based on the assertion that small, rounded cribriform cancer might be graded as Gleason grade 3,10 (link),13 (link),15 (link) specimens with any cribriform pattern were further subdivided by annotating the SC and LC areas. Image 2 shows an example of an annotated slide.
The rare cancer subtypes of ductal19 (link),20 (link) (excluding some papillary patterns that were encompassed in a broader definition of ductal21 (link)), and adenoid cystic/basal cell carcinoma22 (link) were denoted, if present, according to established criteria. To verify all annotations considered to be LC or SC or to have ductal cancer, consensus conferences were held by 4 of us (K.A.I., G.R.K., F.G.L., and M.S.L.), at which annotated slide images were projected on a screen. For each specimen, taking together all pertaining slides, the area sum of each cancer pattern was determined by summation of all digitally annotated foci belonging to that pattern. In this manner, each distinct pattern could be considered individually from a statistical viewpoint. The amount of each pattern per specimen was also expressed as percentage of the total cancer area. However, area sums rather than pattern percentages were used as the main method of analysis to approximate the cancer contribution of each pattern.
To determine the relative tendency of each pattern toward extraprostatic extension or seminal vesicle invasion, the cancer patterns responsible for these findings were tabulated. As a separate analysis, to explore the effect of having a sizable amount of large acinar (LA, or P plus cribriform [C] patterns) cancer, a cut point of P + C patterns forming more than one third of the total cancer area per patient was chosen. The one-third cut point was chosen for its ease of perception at diagnosis and because it produced a category that included 17 cases, allowing meaningful statistical comparison with the other 136.
Publication 2011
Adenoids ARID1A protein, human Carcinoma, Cribriform Cells Conferences Cyst Diagnosis Ductal Carcinoma Malignant Neoplasms Mucinous Adenocarcinoma Mucins Patients Prostatectomy Seminal Vesicles
The following variables were analyzed: demographics (age and sex), clinicopathological features (tumor location, tumor size, histological type, and tumor stage), and treatment with chemotherapy. We defined cecum carcinoma, ascending colon cancer, and right-half transverse colon as right-sided CRC, whereas the rest were classified as left-sided CRCs. The well and moderately differentiated adenocarcinomas were histologically categorized as the well-differentiated type, and the poorly differentiated adenocarcinomas included poorly differentiated adenocarcinoma, mucinous adenocarcinoma, signet ring cell cancer, and undifferentiated cancer. Tumor staging was performed according to the 7th edition of the Union for International Cancer Control-American Joint Committee on cancer classification for CRC.
Preoperative blood sampling was performed to measure the neutrophil, lymphocyte, and platelet levels for the calculation of the NLR, PLR, and SII indices. NLR and PLR were defined as the total number of neutrophils or platelets divided by the total number of lymphocytes. SII was calculated with the formula SII = (P × N)/L, where P, N, and L refer to peripheral platelet, neutrophil, and lymphocyte counts, respectively.
Publication 2017
Adenocarcinoma Blood Platelets Calcibiotic Root Canal Sealer Cancer of Cecum Cancer of Colon Carcinoma, Signet Ring Cell Colon, Ascending Joints Lymphocyte Lymphocyte Count Malignant Neoplasms Mucinous Adenocarcinoma Neoplasms Neoplasms by Site Neutrophil Pharmacotherapy Transverse Colon Undifferentiated Carcinoma

Most recents protocols related to «Mucinous Adenocarcinoma»

This study included 422 patients with PC, 119 patients with benign pancreatic tumors (BPT; 39 chronic pancreatitis, 56 pancreatic serous cystadenomas, and 24 pancreatic mucinous cystadenomas), 98 patients with solid pseudo-papilloma of the pancreas (SPT), 59 patients with pancreatic neuroendocrine tumors (PNET), and 392 healthy controls (HC) from January 2015 to December 2021 at the Harbin Medical University Cancer Hospital. Eight patients with PC, 11 with other pancreatic diseases (OPT; two CP, two SPT, and seven pancreatic serous or mucinous cystadenoma), and nine HC from January 2017 to December 2021 in the Municipal Hospital Affiliated to Taizhou University were also enrolled in this study. The inclusion and exclusion criteria were as follows:1) age ≥ 18 years; 2) pathologically confirmed diagnoses of PC(adenocarcinoma, pancreatic ductal adenocarcinoma, and mucinous adenocarcinoma), neuroendocrine tumor (G1, G2, and G3), solid pseudopapillary neoplasm, chronic pancreatitis, pancreatic serous cystadenoma, and pancreatic mucinous cystadenoma; 3) R0 resection (radical surgical resection); 4) PC pathology at TNM stage I—II; 5) available clinical baseline information; 6) no antitumor therapy performed before surgery; 7) no second primary cancer; 8) no history of autoimmune disorders, hepatitis, nephropathy, coagulation disorders, or HIV infection; and 9) no acute inflammation before surgery.
Each disease group and HC from Harbin Medical University Cancer Hospital were randomly divided into training and testing sets 1 at a ratio of 4:1. The patients and HC from Municipal Hospital Affiliated to Taizhou University were used as testing set 2. Ethical approval for this study was granted by the Harbin Medical University Cancer Hospital and Municipal Hospital Affiliated to Taizhou University Ethics Committee, and all participants provided signed informed consent forms.
Full text: Click here
Publication 2023
Adenocarcinoma Autoimmune Diseases Benign Neoplasm Blood Coagulation Disorders Carcinoma, Pancreatic Ductal Cystadenoma, Mucinous Cystadenoma, Serous Diagnosis Ethics Committees, Clinical Hepatitis Hereditary pancreatitis HIV Infections Inflammation Islet Cell Tumor Kidney Diseases Malignant Neoplasms Mucinous Adenocarcinoma Neoplasms Neuroendocrine Tumors Operative Surgical Procedures Pancreas Pancreatic Diseases Papilloma Patients PC-II Second Primary Cancers Serum Therapeutics
This study was institutionally approved by the Kyoto Prefectural University of Medicine, and each participant provided written informed consent. A total of 117 patients who underwent curative surgery for AEG, classified as Siewert type I or II, at our institute between 2000 and 2016 were included in this study. We precisely defined Siewert type based on pathological mapping and macroscopic measurements of the distance between the tumour epicentre and the esophagogastric junction. Furthermore, we retrospectively analysed clinicopathological features and prognostic outcomes. Finally, we evaluated the compatibility of our findings with the eighth edition of the AJCC/UICC TNM classification system for AEG [7 , 15 ].
The postoperative follow-up program at our institution comprises a regular physical examination as well as laboratory blood tests and chest X-rays every three or six months. Endoscopy and ultrasonography, or computed tomography, were performed annually for the first five years, if possible. All enrolled patients underwent pathological or macroscopic curative resection (R0). Histological types were classified as differentiated (papillary adenocarcinoma, or moderately or well-differentiated adenocarcinoma) or undifferentiated (poorly differentiated or undifferentiated adenocarcinoma, signet-ring cell carcinoma, or mucinous adenocarcinoma) based on the 15th edition of the Japanese Classification of Gastric Carcinoma [16 ]. Patients with bulky metastatic lymph nodes underwent neoadjuvant chemotherapy (NAC). The regimen of NAC was S-1 and cisplatin according to Japanese gastric cancer guidelines [16 ]. Patients who underwent NAC were 10.2% (12/117) of all patients. Patients with pStage II or high underwent postoperative S-1 adjuvant chemotherapy for one year according to the ACTS-GC (Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer) study [17 (link)].
Full text: Click here
Publication 2023
Adenocarcinoma Carcinoma, Signet Ring Cell Chemotherapy, Adjuvant Cisplatin Dietary Fiber Endoscopy, Gastrointestinal Esophagogastric Junction Gastric Cancer Hematologic Tests Japanese Mucinous Adenocarcinoma Neoadjuvant Chemotherapy Neoplasms Nodes, Lymph Operative Surgical Procedures Papillary Adenocarcinoma Patients Pharmaceutical Preparations Physical Examination Radiography, Thoracic SERPINA3 protein, human Treatment Protocols Ultrasonography X-Ray Computed Tomography
A total of 6, 020 consecutive patients with CRC who were admitted to Shanghai Changzheng Hospital from July 2010 to June 2021 were selected. The study was approved by the ethics committee of Shanghai Changzheng hospital. The clinical data collected included age, gender, tumor metastasis, HBV carrier status, blood type, CEA, CA199, AFP, primary tumor location, primary tumor diameter, tissue type, degree of differentiation, and depth of tumor invasion. Locations of the primary tumor were divided into left colon, right colon, and rectum. Diameter of the primary tumor was divided into ≤3 cm and >3 cm according to the size. Tissue types were divided into adenocarcinoma and other types (carcinoid, signet ring cell carcinoma, mucinous adenocarcinoma, etc.). Degrees of differentiation were divided into undifferentiated-poor differentiation and medium-well differentiation. Depths of invasion were divided into T1-2 group and T3-4 according to the TNM staging standard formulated by AJCC. Each patient selectively underwent X-ray, abdominal B-ultrasound, chest CT, abdomen CT, abdominal MRI, or PET-CT according to the diagnosis and treatment needs.
Full text: Click here
Publication 2023
Abdomen Abdominal Cavity Adenocarcinoma Carcinoid Tumor Carcinoma, Signet Ring Cell Chest Colon Diagnosis Ethics Committees, Clinical Gender Histocompatibility Testing Mucinous Adenocarcinoma Neoplasm Invasiveness Neoplasm Metastasis Neoplasms Neoplasms by Site Patients Radiography Rectum Scan, CT PET Ultrasonography
We retrospectively analyzed clinical data of all patients with dMMR/MSI-H gastrointestinal malignancies who received preoperative PD1 blockade immunotherapy with or without chemotherapy in Ward 3, Gastrointestinal Cancer Center, Peking University Cancer Hospital from January 1, 2020 to September 30, 2022. Preoperative PD-1 blockade immunotherapy is recommended for patients with dMMR/MSI-H detected by molecular detection before treatment. This cohort was a series of sequential cases.
The inclusion criteria were: (1) Age ≥ 18 and ≤ 90 years; (2) Eastern Collaborative Oncology Group performance status score 0–2; (3) gastrointestinal malignancies: gastric cancer, duodenal carcinoma, or colorectal cancer; (4) adenocarcinoma or mucous adenocarcinoma confirmed by endoscopic biopsy; (5) clinical stage II–IV according to imaging examinations [spiral computed tomography, magnetic resonance imaging, positron emission tomography–computed tomography (PET-CT) or ultrasound colonoscopy]; and (6) MSI and MMR status confirmed by immumohistochemical staining, polymerase chain reaction (PCR) and next-generation sequencing (NGS). The exclusion criteria included: (1) Initially unresectable metastasis lesion; and (2) diseases of the immune system. This study was approved by the Ethics Committee of Peking University Cancer Hospital (2022YJZ39) and it conformed to the provisions of the Declaration of Helsinki.
Publication 2023
Adenocarcinoma Biopsy Colonoscopy Colorectal Carcinoma Duodenal Cancer Endoscopy Ethics Committees, Clinical Gastric Cancer Gastrointestinal Cancer Immune System Diseases Immunotherapy Malignant Neoplasms Mucinous Adenocarcinoma Neoplasm Metastasis Neoplasms Patients Pharmacotherapy Physical Examination Polymerase Chain Reaction Scan, CT PET Tomography, Spiral Computed Ultrasonography
Population-based information was retrieved from the SEER program. The inclusion criteria were as follows: (1) age older than 18 years; (2) pathologic confirmation was adenocarcinoma, mucinous adenocarcinoma, mucin-producing adenocarcinoma, mucinous cyst-adenocarcinoma, signet ring cell carcinoma, papillary adenocarcinoma, tubular adenocarcinoma, adenocarcinoma intestinal type, carcinoma diffuse type, adenocarcinoma with mixed subtype; (3) patients who received radical operation; (4) the sixth edition AJCC stage was IB (T1N1M0 or T2aN0M0).
The exclusion criteria were as follows: (1) patients who only lived for a month or less; (2) regional positive lymph nodes were 3, 4, 5, and 6 among T1N1 (1–6 positive nodes) M0 patients because all these data were translated to conform the eighth edition of the AJCC system to get a sufficient follow-up time; (3) Patients with incomplete demographic, clinicopathological, therapy or follow-up data were eliminated from the study. In the end, 1889 patients were enrolled in the research. The process of patient selection is presented in Fig. 1.

The workflow of the patient selection process

Full text: Click here
Publication 2023
Adenocarcinoma Adenocarcinoma, Tubular Carcinoma Carcinoma, Signet Ring Cell Cyst Intestines Mucinous Adenocarcinoma Mucocele Nodes, Lymph Papillary Adenocarcinoma Patients Therapeutics

Top products related to «Mucinous Adenocarcinoma»

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
Sourced in Germany, United States, United Kingdom, Spain, Netherlands, Canada, France, Japan, China, Italy, Switzerland, Australia, Sweden, India, Singapore, Denmark, Belgium
The RNeasy kit is a laboratory equipment product that is designed for the extraction and purification of ribonucleic acid (RNA) from various biological samples. It utilizes a silica-membrane-based technology to efficiently capture and isolate RNA molecules.
Sourced in United States, China
The MGC-803 is a laboratory equipment product manufactured by Thermo Fisher Scientific. It is designed for general laboratory use, but its core function is not specified in the information provided. A more detailed and unbiased description cannot be provided without the risk of extrapolation or interpretation.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, United Kingdom, China
The LS174T is a cell line derived from a human colon adenocarcinoma. It is a widely used model for the study of intestinal epithelial cells and their response to various stimuli.
Sourced in China, United States
The HO8910 is a laboratory equipment used for cell culture applications. It provides a controlled environment for the growth and maintenance of cells. The core function of the HO8910 is to maintain optimal temperature, humidity, and CO2 levels to support the viability and proliferation of cells in culture.
Sourced in United States, China, Germany, United Kingdom, France, Italy, Canada, Switzerland, Japan, Australia, Austria, Belgium, Brazil, India, Spain, Ireland, Netherlands, Israel
DMEM medium is a commonly used cell culture medium formulated to support the growth and maintenance of a variety of cell types in vitro. It provides essential nutrients, vitamins, and other components required for cell proliferation and survival.
Sourced in United States, China, Germany, Japan, United Kingdom, Spain, Canada, France, Australia, Italy, Switzerland, Sweden, Denmark, Lithuania, Belgium, Netherlands, Uruguay, Morocco, India, Czechia, Portugal, Poland, Ireland, Gabon, Finland, Panama
The NanoDrop 2000 is a spectrophotometer designed for the analysis of small volume samples. It enables rapid and accurate quantification of proteins, DNA, and RNA by measuring the absorbance of the sample. The NanoDrop 2000 utilizes a patented sample retention system that requires only 1-2 microliters of sample for each measurement.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

More about "Mucinous Adenocarcinoma"

Mucinous adenocarcinoma is a type of malignant neoplasm characterized by the presence of mucin within the tumor cells.
This subtype of adenocarcinoma can occur in various organs, including the colon, rectum, pancreas, and ovaries.
Compared to other adenocarcinoma subtypes, mucinous adenocarcinoma is often associated with a poorer prognosis due to its unique biological features and clinical presentation.
Researchers and clinicians can leverage the power of PubCompare.ai's AI-driven platform to enhance reproducibility and accuracy in the study of this complex disease.
The platform's state-of-the-art technology enables seamless research, allowing users to locate the best protocols from literature, preprints, and patents through intelligent comparisons and data-driven insights.
Enhancing the understanding of mucinous adenocarcinoma can be facilitated by the use of various cell culture media, such as RPMI 1640 and DMEM, as well as techniques like the RNeasy kit and NanoDrop 2000 for RNA extraction and quantification.
Cell lines like MGC-803, LS174T, and HO8910 can also be utilized to study the biology and behavior of this disease.
By leveraging the power of PubCompare.ai and employing a range of research tools and techniques, scientists and clinicians can advance the understanding of mucinous adenocarcinoma, ultimately leading to improved diagnostic methods, treatment strategies, and patient outcomes.